查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970845

慢性腎臟病治療市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、最終用戶、地區和競爭對手分類，2021-2031年

Chronic Kidney Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球慢性腎臟病治療市場預計將從 2025 年的 370.7 億美元成長到 2031 年的 488.6 億美元，複合年成長率為 4.71%。

該領域涵蓋了治療腎功能衰退的多種方案，從藥物治療和透析到腎臟移植。推動該領域發展的主要因素是人口老化，這使得人們更容易患上腎衰竭，以及高血壓和糖尿病等文明病在全球範圍內的日益流行。國際腎臟病學會強調了醫療解決方案的迫切性，並估計到2024年，全球將有超過8.5億人患有某種形式的腎臟疾病。

市場概覽
預測期 2027-2031
市場規模：2025年 370.7億美元
市場規模：2031年 488.6億美元
複合年成長率：2026-2031年 4.71%
成長最快的細分市場 診斷段
最大的市場 北美洲

另一方面，由於先進替代療法和長期腎臟護理費用高昂，市場面臨巨大的障礙。在許多發展中地區，由於缺乏完善的醫療基礎設施和全面的報銷機制，很大一部分人口無法獲得必要的治療。這些經濟差距和財務障礙是重大挑戰，有可能嚴重限制全球治療產業的成長和擴張。

市場促進因素

糖尿病腎臟病患疾病率的不斷上升是全球慢性腎臟病治療市場的主要驅動力。糖尿病患者的高血糖值會逐漸損害腎臟的過濾功能，最終導致糖尿病腎臟病。這佔全球末期腎臟病病例的很大一部分。這種關聯導致需要治療性介入和長期管理的患者數量持續成長。根據國際糖尿病聯盟（IDF）於2025年4月發布的第11版《糖尿病地圖集》，全球11.1%的成年人患有糖尿病，構成了一個龐大的高危險群，極易發生腎臟併發症。

同時，由於新型藥物療法和生物製藥的突破性進展，市場正在經歷一場變革。這些治療方法和生物製劑不僅旨在控制症狀，而且旨在延緩疾病進展。鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑的廣泛應用正在創造可觀的收入，並有助於改善患者照護。例如，勃林格殷格翰在2025年4月的研發投資報告中宣布，其慢性腎臟病治療藥物恩格列淨 (Jardiance) 的銷售額成長了14.6%，達到84億歐元。鑑於目前可用的治療方法選擇有限，此類藥物的供應至關重要。根據美國腎臟基金會統計，2024年美國僅有28,492名患者接受了腎臟移植手術，凸顯了透析和藥物治療的高度依賴性。

市場挑戰

先進替代療法和長期腎臟護理的高昂費用是全球慢性腎臟病治療市場擴張的主要障礙。儘管腎衰竭的發生率不斷上升，但移植和透析等手術的高成本使許多患者無法獲得必要的治療。在醫療基礎設施和報銷體係不完善的發展中地區，這個問題尤其嚴重。因此，經濟限制阻礙了治療方案的推廣，使市場無法充分發揮不斷成長的患者群體的經濟潛力。

根據國際腎臟病學會2024年的數據，僅有28%的參與調查的低收入和中低收入國家能夠獲得完全由公共資金支持的血液透析服務。這一數字凸顯了阻礙這些地區市場擴張的嚴重經濟差距。由於缺乏充足的資金支持，腎臟疾病管理中的關鍵臨床需求無法轉化為永續的商業性需求，從而阻礙了整個行業的成長，並將產生收入幾乎完全限制在擁有完善醫療保健體系的已開發國家。

市場趨勢

利用穿戴式和攜帶式技術進行居家透析的轉變正在改變市場格局，緩解了傳統醫療機構治療帶來的經濟和後勤挑戰。這一趨勢正在催生高度互聯且方便用戶使用的透析系統，使患者能夠在家庭中管理末期腎功能衰竭，從而提高生活品質並最大限度地降低醫院感染的風險。在遠端醫療的臨床計劃和有利的報銷政策的支持下，這項轉變將減輕醫療機構的負擔。 DaVita 於 2025 年 5 月發布的《2024 年社區護理報告》顯示，超過 15% 的患者正在接受居家透析治療，這表明醫療服務結構正在向分散式模式轉變，這印證了居家透析的廣泛應用。

同時，人工智慧（AI）在風險分層和疾病早期檢測方面的應用，正在為精準腎臟醫學樹立新的標準。這使得治療的重點從被動應對轉向主動預測。透過利用新型生物標記和先進的機器學習演算法，醫療專業人員能夠比以往更早地識別出腎功能快速下降風險較高的患者，從而及時進行適當的治療，延緩透析的需求。這項技術進步得益於商業性應用和保險覆蓋範圍的擴大。例如，Renalistics在2025年3月的半年報告中指出，私人保險對診斷測試的報銷比例增加了28%，凸顯了人工智慧驅動的診斷技術日益成長的臨床和市場價值。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：慢性腎臟病治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（診斷、治療、透析、其他）
    • 按最終用戶（醫院、診斷檢查室、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美慢性腎臟病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲慢性腎臟病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區慢性腎臟病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲慢性腎臟病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲慢性腎臟病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球慢性腎臟病治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17682

The Global Chronic Kidney Disease Treatment Market is projected to expand from USD 37.07 Billion in 2025 to USD 48.86 Billion by 2031, registering a CAGR of 4.71%. This sector covers various therapeutic measures designed to handle declining renal function, ranging from pharmacological treatments and dialysis to kidney transplantation. Growth is largely fueled by the rising global prevalence of lifestyle-related conditions such as hypertension and diabetes, in addition to an aging population more prone to renal failure. Highlighting the urgent need for medical solutions, the International Society of Nephrology estimated in 2024 that over 850 million people worldwide were suffering from some form of kidney disease.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 37.07 Billion
Market Size 2031USD 48.86 Billion
CAGR 2026-20314.71%
Fastest Growing SegmentDiagnosis Segment
Largest MarketNorth America

Conversely, the market encounters significant hurdles due to the exorbitant costs linked to advanced replacement therapies and long-term renal care. In numerous developing areas, the absence of adequate healthcare infrastructure and comprehensive reimbursement systems denies a substantial portion of the populace access to essential treatments. These economic disparities and financial obstacles represent a major challenge that threatens to severely limit the wider growth and reach of the global treatment industry.

Market Driver

The rising prevalence of diabetes-related nephropathy acts as a major catalyst for the Global Chronic Kidney Disease Treatment Market. Elevated blood sugar levels in diabetics gradually impair the renal filtration mechanism, resulting in diabetic kidney disease, which constitutes a significant share of end-stage renal disease cases worldwide. This connection guarantees a steady and increasing stream of patients needing therapeutic intervention and chronic management. As noted in the 'IDF Diabetes Atlas 11th Edition' released by the International Diabetes Federation in April 2025, 11.1% of the global adult population is living with diabetes, forming a vast pool of individuals at high risk for renal complications.

Simultaneously, the market is being transformed by breakthroughs in novel pharmacological therapies and biologics that aim to slow disease progression rather than simply address symptoms. The widespread adoption of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors has generated significant revenue and enhanced patient care. For example, Boehringer Ingelheim reported in their April 2025 R&D investment update that sales of Jardiance, a drug for chronic kidney disease, increased by 14.6% to EUR 8.4 billion. This uptake in pharmaceuticals is crucial given the limited availability of cures; the American Kidney Fund noted that only 28,492 patients in the United States received a transplant in 2024, highlighting the heavy dependence on dialysis and medication.

Market Challenge

The exorbitant expenses tied to advanced replacement therapies and long-term renal care create a significant obstacle to the expansion of the Global Chronic Kidney Disease Treatment Market. Despite the increasing incidence of renal insufficiency, the high cost of procedures such as transplantation and dialysis precludes a large segment of patients from receiving essential care. This problem is especially severe in developing regions lacking sufficient healthcare infrastructure and robust reimbursement frameworks. Consequently, the market fails to realize the full economic potential of the expanding patient base, as financial limitations restrict the uptake of therapeutic solutions.

Data from the International Society of Nephrology in 2024 indicates that full public funding for hemodialysis was accessible in merely 28% of participating low and lower-middle-income nations. This figure underscores the profound economic inequality that limits market reach in these areas. In the absence of sufficient funding structures, the critical clinical requirement for kidney disease management cannot evolve into viable commercial demand, thereby hindering broader industry growth and restricting revenue generation largely to developed countries with established healthcare support.

Market Trends

The movement toward home-based dialysis using wearable and portable technologies is transforming the market by mitigating the financial and logistical challenges of conventional in-center care. This trend involves the creation of connected, easy-to-use dialysis systems that enable patients to handle end-stage renal disease from home, enhancing their quality of life while minimizing the risk of hospital-acquired infections. Supported by clinical advocacy for remote care and favorable reimbursement rules, this shift relieves pressure on strained healthcare facilities. As evidence of this growing adoption, DaVita's '2024 Community Care' report from May 2025 noted that over 15% of their patients performed dialysis at home, indicating a structural shift toward decentralized treatment.

Concurrently, the incorporation of artificial intelligence for risk stratification and early disease detection is setting a new standard in precision renal care, shifting the focus from reactive treatment to predictive intervention. By utilizing novel biomarkers and sophisticated machine learning algorithms, medical professionals can detect patients prone to rapid kidney function decline much earlier than before, allowing for timely treatments that delay the need for dialysis. This technological progress is validated by rising commercial adoption and payer coverage; for instance, Renalytix reported in their March 2025 'Half-year Report' that revenue from commercial insurance reimbursed testing rose by 28%, highlighting the growing clinical and market value of AI-powered diagnostics.

Key Market Players

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Chronic Kidney Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Kidney Disease Treatment Market, By Product Type

  • Diagnosis
  • Treatment
  • Dialysis
  • Others

Chronic Kidney Disease Treatment Market, By End User

  • Hospital
  • Diagnostic Laboratories
  • Other

Chronic Kidney Disease Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Kidney Disease Treatment Market.

Available Customizations:

Global Chronic Kidney Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Kidney Disease Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Diagnosis, Treatment, Dialysis, Others)
    • 5.2.2. By End User (Hospital, Diagnostic Laboratories, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Chronic Kidney Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chronic Kidney Disease Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Chronic Kidney Disease Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Chronic Kidney Disease Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By End User

7. Europe Chronic Kidney Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chronic Kidney Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Chronic Kidney Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Chronic Kidney Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Chronic Kidney Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Chronic Kidney Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Chronic Kidney Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chronic Kidney Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Chronic Kidney Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Chronic Kidney Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Chronic Kidney Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Chronic Kidney Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Chronic Kidney Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chronic Kidney Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Chronic Kidney Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Chronic Kidney Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By End User

10. South America Chronic Kidney Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chronic Kidney Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Chronic Kidney Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Chronic Kidney Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chronic Kidney Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. Bayer AG
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. GlaxoSmithKline PLC
  • 15.7. Merck & Co. Inc.
  • 15.8. Pfizer Inc.
  • 15.9. Sysmex Corporation
  • 15.10. Teva Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer